학술논문
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia.
Document Type
Letter
Author
Deodato, Marina; Frustaci, Anna Maria; Sportoletti, Paolo; Laurenti, Luca; Murru, Roberta; Visentin, Andrea; Reda, Gianluigi; Mauro, Francesca Romana; Quaresmini, Giulia; Vanazzi, Anna; Vitale, Candida; Orsucci, Lorella; Massaia, Massimo; Sanna, Alessandro; Motta, Marina; Ibatici, Adalberto; Ferrarini, Isacco; Borella, Chiara; Varettoni, Marzia; Tani, Monica
Source
Subject
*CHRONIC lymphocytic leukemia
*COVID-19 pandemic
*SARS-CoV-2
*ATTITUDE change (Psychology)
*TUMOR lysis syndrome
*
*
*
*
Language
ISSN
1042-8194
Abstract
Since the beginning of COVID-19 pandemic in February 2020 until March 2021, 130 consecutive patients received venetoclax ± anti-CD20 MoAb in 21 centers of central-northern Italy; 37% were treated in Lombardy, the region most impacted by COVID-19. The impact of CLL treatment with target agents on COVID-19 infection is not fully understood, while CD20-targeting agents, by producing a decrease in B-lymphocytes, represent a risk factor for severe COVID-19 infections [[3]]. Keywords: Chronic lymphocytic leukemia; venetoclax; Rituximab; COVID-19 EN Chronic lymphocytic leukemia venetoclax Rituximab COVID-19 1985 1988 4 08/22/22 20220801 NES 220801 Chronic lymphocytic leukemia (CLL) patients diagnosed with severe acute respiratory syndrome coronavirus-2 disease (COVID-19) are at high risk of hospitalization and death independently of disease phase or treatment status. [Extracted from the article]